- 同
- colfosceril palmitate
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/12/08 21:40:57」(JST)
[Wiki en表示]
Colfosceril palmitate
|
Systematic (IUPAC) name |
2,3-di(hexadecanoyloxy)propyl 2-trimethylazaniumylethyl phosphate
|
Clinical data |
Trade names |
Exosurf |
AHFS/Drugs.com |
International Drug Names |
Identifiers |
CAS Number |
63-89-8 Y |
ATC code |
R07AA01 |
PubChem |
CID: 6138 |
ChemSpider |
5908 Y |
UNII |
319X2NFW0A Y |
KEGG |
D03585 Y |
ChEMBL |
CHEMBL1200737 N |
Synonyms |
[2-({[2,3-bis(hexadecanoyloxy)propyl] phosphonato}oxy)ethyl]trimethylazanium |
Chemical data |
Formula |
C40H80NO8P |
Molecular mass |
734.039 g/mol |
SMILES
-
O=C(OCC(OC(=O)CCCCCCCCCCCCCCC)COP([O-])(=O)OCC[N+](C)(C)C)CCCCCCCCCCCCCCC
|
InChI
-
InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3 Y
-
Key:KILNVBDSWZSGLL-UHFFFAOYSA-N Y
|
N (what is this?) (verify) |
Colfosceril palmitate (trade name Exosurf) is a drug used as a pulmonary surfactant.[1] It is a drug that is used in surfactant deficient conditions such as IRDS in newborns.
See also
- Dipalmitoylphosphatidylcholine
References
- ^ Rubin, B. K. (1996). "Therapeutic aerosols and airway secretions". Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine 9 (1): 123–130. doi:10.1089/jam.1996.9.123. PMID 10160202.
Other respiratory system products (R07)
|
|
Lung surfactants |
|
|
Respiratory stimulants |
- Almitrine
- Amiphenazole
- Bemegride
- Dimefline
- Doxapram
- Etamivan
- GAL-021
- Mepixanox
- Nikethamide
- Pentetrazol
- Prethcamide
|
|
5-HT4 receptor agonists |
|
|
Other agents for treating respiratory depression |
- Ivacaftor (+ lumacaftor)
- Nitric oxide
- BW373U86
- CX-546
- CX-717
|
|
Index of the respiratory system
|
|
Description |
- Anatomy
- Physiology
- Development
|
|
Disease |
- Congenital
- Neoplasms and cancer
- Chest trauma
- Infection
- common cold
- pneumonia
- tuberculosis
- Other
- Symptoms and signs
|
|
Treatment |
- Procedures
- Drugs
- nasal
- throat
- obstructive airway diseases
- cough and cold
- histaminergics
- pulmonary arterial hypertension
- other
- Surgery
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials.
- Zhang L1, Cao HY2, Zhao S3, Yuan LJ4, Han D1, Jiang H5, Wu S3, Wu HM6.
- Pulmonary pharmacology & therapeutics.Pulm Pharmacol Ther.2015 Oct;34:46-54. doi: 10.1016/j.pupt.2015.08.005. Epub 2015 Aug 18.
- BACKGROUND: The utilization of multiple natural and synthetic products in surfactant replacement therapies in treatment of neonatal respiratory distress syndrome (NRDS) prompted us to take a closer looks at these various therapeutic options and their efficacies. The purpose of our study was to evalu
- PMID 26296793
- Contributory roles of innate properties of cetyl alcohol/gelucire nanoparticles to antioxidant and anti-inflammation activities of quercetin.
- Bi L1, Wehrung D, Oyewumi MO.
- Drug delivery and translational research.Drug Deliv Transl Res.2013 Aug;3(4):318-29. doi: 10.1007/s13346-013-0130-6.
- The protective effects of synthetic lung surfactant Exosurf® (containing cetyl alcohol) against endotoxin-induced inflammation have been demonstrated in the literature. Thus, it is envisioned that nanoparticles loaded with quercetin (Q-NPs) prepared with binary mixtures of cetyl alcohol (CA) and Ge
- PMID 25788280
- Properties of mixed monolayers of clinical lung surfactant, serum albumin and hydrophilic polymers.
- Minkov I1, Mircheva K, Grozev N, Tz I, Panaiotov I.
- Colloids and surfaces. B, Biointerfaces.Colloids Surf B Biointerfaces.2013 Jan 1;101:135-42. doi: 10.1016/j.colsurfb.2012.05.038. Epub 2012 Jun 15.
- It is now established that the surface activity of the clinically used lung surfactant is reduced by serum proteins and can be restored by adding the hydrophilic polymers. The mechanisms of lung surfactant inactivation by serum proteins and restoring effect by the hydrophilic polymers remain not com
- PMID 22796783
Japanese Journal
- Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf
- Double-blind randomised trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700-1100 grams : effects on mortality rate. American Exosurf Neonatal Study Groups I and IIa
- Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf
Related Links
- Exosurf Neonatal Drug Information from Drugs.com. Includes Exosurf Neonatal side effects, interactions and indications. ... Drugs.com provides accurate and independent information on more than 24,000 prescription ...
- Exosurf [ek´so-surf″] a commercially available synthetic surfactant preparation, which is used in the treatment of respiratory distress syndrome of the ... An increased proportion of patients with both intraventricular hemorrhage (IVH ...
Related Pictures